Eagle Health Investments LP boosted its stake in shares of Icon Plc (NASDAQ:ICLR – Free Report) by 35.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 247,090 shares of the medical research company’s stock after purchasing an additional 64,500 shares during the quarter. Icon comprises 9.9% of Eagle Health Investments LP’s portfolio, making the stock its 2nd largest holding. Eagle Health Investments LP owned approximately 0.31% of Icon worth $45,025,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in ICLR. WINTON GROUP Ltd bought a new stake in Icon during the second quarter worth approximately $254,000. Daiwa Securities Group Inc. boosted its position in Icon by 19.3% during the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock worth $4,094,000 after purchasing an additional 4,546 shares during the period. Frontier Capital Management Co. LLC boosted its position in Icon by 97.6% during the second quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock worth $10,379,000 after purchasing an additional 35,253 shares during the period. Peapack Gladstone Financial Corp bought a new stake in Icon during the second quarter worth approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Icon by 58.7% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after purchasing an additional 289 shares during the period. Institutional investors own 95.61% of the company’s stock.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the company. Barclays decreased their target price on Icon from $200.00 to $120.00 and set an “equal weight” rating for the company in a research report on Monday, March 9th. Rothschild & Co Redburn set a $100.00 target price on Icon and gave the company a “neutral” rating in a report on Tuesday, February 17th. Robert W. Baird set a $119.00 target price on Icon in a report on Friday, February 13th. JPMorgan Chase & Co. lowered their target price on Icon from $175.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday. Finally, TD Cowen raised Icon from a “hold” rating to a “buy” rating and lowered their target price for the company from $183.00 to $120.00 in a report on Wednesday, February 18th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $145.67.
Icon Price Performance
Shares of NASDAQ:ICLR opened at $115.09 on Thursday. Icon Plc has a 1-year low of $66.57 and a 1-year high of $211.00. The firm has a market capitalization of $9.29 billion, a PE ratio of 15.57, a PEG ratio of 2.97 and a beta of 1.23. The business’s 50 day moving average is $110.01 and its 200-day moving average is $143.38. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31.
About Icon
Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.
Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.
Featured Stories
- Five stocks we like better than Icon
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
